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Background: Carbapenemase-producing  Escherichia 
coli  are increasing worldwide. In recent years, an 
increase in OXA-244-producing  E. coli  isolates has 
been seen in the national surveillance of carbap-
enemase-producing organisms in Denmark. Aim: 
Molecular characterisation and epidemiological 
investigation of OXA-244-producing  E. coli  isolates 
from January 2016 to August 2019. Methods: For the 
epidemiological investigation, data from the Danish 
National Patient Registry and the Danish register of 
civil registration were used together with data from 
phone interviews with patients. Isolates were char-
acterised by analysing whole genome sequences 
for resistance genes, MLST and core genome MLST 
(cgMLST). Results: In total, 24 OXA-244-producing  E. 
coli  isolates were obtained from 23 patients. Among 
the 23 patients, 13 reported travelling before detection 
of the E. coli isolates, with seven having visited coun-
tries in Northern Africa. Fifteen isolates also carried 
an extended-spectrum beta-lactamase gene and one 
had a plasmid-encoded AmpC gene. The most com-
mon detected sequence type (ST) was ST38, followed 
by ST69, ST167, ST10, ST361 and ST3268. Three clonal 
clusters were detected by cgMLST, but none of these 
clusters seemed to reflect nosocomial transmission in 
Denmark. Conclusion: Import of OXA-244  E. coli  iso-
lates from travelling abroad seems likely for the major-
ity of cases. Community sources were also possible, 
as many of the patients had no history of hospitalisa-
tion and many of the  E. coli  isolates belonged to STs 
that are present in the community. It was not possible 
to point at a single country or a community source as 
risk factor for acquiring OXA-244-producing E. coli.
Introduction
Carbapenems are used for treatment of infections with 
multi-resistant Gram-negative bacteria, e.g. extended-
spectrum beta-lactamase (ESBL)-producing Escherichia 
coli. Carbapenemase production can be caused by 
the presence of various carbapenemases. One of the 
frequently detected carbapenemases in Europe is 
OXA-48. Besides OXA-48, 17 other variants belong to 
the OXA-48 carbapenemase group) [1] including OXA-
244. In comparison to OXA-48, OXA-244 has a single 
amino acid substitution (Arg-222-Gly) and has reduced 
carbapenemase activity [2]. It was first described in 
Spain from a  Klebsiella pneumoniae  isolate in 2013 
[2]. Subsequently, OXA-244-producing  E. coli  isolates 
were reported from patients in the United Kingdom 
(UK), France and Egypt, from a healthy person in 
Germany, from a Dutch traveller and her spouse vis-
iting Indonesia, from river water in Algeria and from 
an estuary in Lebanon [3-8]. OXA-244-producing  E. 
coli can be a challenge for clinical laboratories as they 
may not grow on selective media used for detection of 
carbapenemase producers or may not be detected by 
carbapenemase-specific tests [4]. Furthermore, OXA-
244-producing  E. coli  isolates can have low minimal 
inhibitory concentrations (MIC) for temocillin and 
meropenem [4,9].
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On 18 February 2020, the European Centre for 
Disease Prevention and Control (ECDC) published 
a Rapid Risk Assessment (RRA) on the increase in 
OXA-244-producing  E. coli, including in Denmark [10]. 
Before the invitation to contribute data to the RRA, 
the national reference laboratory at Statens Serum 
Institute (SSI), Copenhagen had already detected an 
increase in OXA-244-producing  E. coli  in Denmark, 
whereas bla OXA-244 was not detected from other carbap-
enemase-producing Enterobacterales.
In this study, we characterised by whole genome 
sequencing (WGS), all OXA-244-producing  E. 
coli isolates submitted to SSI during 2016 through July 
2019. Data from the Danish National Patient Registry 
were used for epidemiological investigation together 
with data from phone interviews with patients infected/
colonised with OXA-244-producing  E. coli  isolates 
from January 2018 through July 2019. Our aim was to 
investigate if the increase in OXA-244-producing  E. 
coli was related to hospital outbreaks or was related to 
travel from abroad.
Methods
Setting
Before 2018, Danish departments of clinical microbiol-
ogy (DCM) submitted on voluntary basis, carbapene-
mase-producing organisms (CPO) for verification and 
genotyping at the national reference laboratory at SSI 
[11]. On 5 September 2018, the Danish Health Authority 
made CPO notifiable and published a national guide-
line to prevent the spread of CPO, including criteria for 
screening for CPO colonisation after hospitalisation 
abroad [12]. The CPO isolates are both from screen-
ing, e.g. patients travelling abroad or during outbreak 
investigations, and clinical samples from hospitals and 
primary care facilities detected during routine suscep-
tibility testing.
Screening isolates are obtained using faecal material 
from a faecal swabs added to a selective Brain heart 
infusion (BHI) broth with 0.25 mg/L meropenem. After 
overnight incubation (18-24 hours) at 35°C, 10 µl from 
the BHI broth are plated in a selective agar e.g. chro-
mID CARBA SMART (bioMérieux, Ballerup, Denmark) 
Figure 1
Carbapenemase-producing Escherichia coli, Denmark, January 2015–August 2019 (n = 237)
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and incubated for 18–24 h at 35°C [13]. Isolates (from 
clinical and screenings samples) suspected to be 
carbapenemase-producing according to the European 
Committee on Antimicrobial Susceptibility Testing 
(EUCAST) guidelines [14,15] are submitted to SSI from 
the Danish DCM [11].
Samples
From January 2016 to August 2019, 24 OXA-244-
producing  E. coli  isolates from 23 patients were 
detected in Denmark as part of the national surveil-
lance of CPO. For patients from whom more than one 
OXA-244-producing E. coli  isolate was reported within 
a rolling 12-month period, only the first isolate was 
included in the study. From a single patient, two iso-
lates were included as the second isolate carried an 
additional carbapenemase gene. The numbers of OXA-
244 producing  E. coli  isolates were compared with 
the total numbers of carbapenemase-producing  E. 
coli during the same period.
Epidemiological data and sources
Available data on travel history abroad 6 months before 
detection of the OXA-244-producing  E. coli  isolates 
were, as part of the national surveillance, reported 
by the DCM or by the responsible clinician/physician. 
Information on age, sex and postal code for residence 
was collected from the Danish Civil Registration 
System. Furthermore, patients found positive with 
OXA-244-producing  E. coli  during January 2018 to 
August 2019 (or their parents if children under 15 years 
of age) were interviewed by phone if possible during 
the summer of 2019, using a questionnaire created for 
this study containing questions on travelling within 6 
months before date of sampling, food consumption 
and animal contact.
For investigation of possible nosocomial transmission 
in Denmark, hospitalisation data were retrieved from 
the DNPR for all patients during the period November 
2015 to February 2019. The DNPR data included admin-
istration data, diagnoses, examinations and treatment 
procedures. Administration data included among oth-
ers; hospital and department codes, dates of admission 
and discharge on patient level [16]. On 1 February 2019, 
the coding procedure for DNPR changed. Therefore, 
DNPR hospital data were only available until 1 February 
2019 for epidemiological analysis in the present study.
Table 1
Sample information, demographic data and travel history for patients with OXA-244-producing Escherichia coli, Denmark, 
January 2016–August 2019 (n = 23)
Patient 
number Sample date Sample Sample site Region
Age group 
(years)a Sex Travel
b
1 May 2016 Urine General practitioner Capital 31–50 Female No travel
2 Nov 2016 Urine Emergency department Zealand 51–65 Male No information
3 Jun 2017 Urine Hospital Southern Denmark 31–50 Female No travel
4 Dec 2017 Urine General practitioner Southern Denmark 51–65 Female No information
5 Feb 2018 Blood Hospital Southern Denmark 51–65 Female Greece
6 Feb 2018 Urine General practitioner Zealand > 65 Female No
7 May 2018 Faeces Hospital Capital > 65 Female Egypt
8 Jun 2018 Urine General practitioner Capital 3–10 Female No information
9 Jun 2018 Urine Hospital Central Denmark > 65 Female No travel
10 Aug 2018 Urine General practitioner Southern Denmark > 65 Female Tunisia
11 Sep 2018 Blood Hospital Zealand > 65 Male Poland, Austria
12 Sep 2018 Faeces Emergency department Capital 31–50 Female Egypt, Turkey
13 Oct 2018 Urine General practitioner North Denmark 31–50 Female No travel
14 Feb 2019 Urine Hospital Capital > 65 Female Egypt
15 Mar 2019 Faeces Emergency department Capital > 65 Male India
16 Apr 2019 Urine General practitioner Central Denmark > 65 Female Egypt, Turkey, Italy
17 May 2019 Urine Hospital Capital 3–10 Female Sweden, Portugal
18 May 2019 Urine General practitioner Southern Denmark 60 Female Germany
19 Jun 2019 Urine General practitioner Southern Denmark 31–50 Female Egypt
20 May 2019 Urine General practitioner Central Denmark > 65 Female No
21 Jun 2019 Urine General practitioner Southern Denmark > 65 Female Egypt
22 Jun 2019 Urine Hospital Central Denmark 51–65 Female No information
23 Jul 2019 Urine Hospital Southern Denmark > 65 Female Spain
a The age of the patients ranged from 5 to 79 years, with a median of 58 years.
b Travel 6 months before the OXA-244-producing Escherichia coli was detected.
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Whole genome sequencing and in silico 
analysis
The genomic DNA was extracted (DNeasy Blood and 
Tissue Kit, Qiagen, Copenhagen, Denmark), with sub-
sequent library construction (Nextera Kit, Illumina, 
Little Chesterford, UK) and finally sequenced (MiSeq 
or Nextseq, Illumina) according to the manufacturer’s 
instructions to obtain paired-end reads of 2x250 or 
2X150 bp in length. Quality control was performed 
on the raw reads, using the Bifrost pipeline at SSI 
(https://github.com/ssi-dk/bifrost) with accepted 
average coverage of 30.00x or above. The WGS data 
were either used as raw data or de novo assembled 
using the assemblies generated with SKESA in Bifrost. 
The raw reads of all 24 isolates were assembled into 
draft genomes using SKESA version 2.2 in the Bifrost 
pipeline.
Sequences are available from GenBank under acces-
sion number PRJEB36710.
Resistance genes were identified with ResFinder ver-
sion 2.1 [17] (included in the Bifrost pipeline), using 
a threshold of 100% identities for identifying genes 
encoding beta-lactamases and carbapenemases, and 
Figure 2
OXA-244-producing Escherichia coli by date of detection and region, Denmark, January 2016–August 2019 (n = 24 isolates)
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98.00% ID for all other genes encoding transferable 
antimicrobial resistance. Two different MLST schemes 
were used, i.e. the Achtman scheme (MLST 1) [18] and 
the Pasteur scheme (MLST 2) [19].
Phylogenetic analyses
The contigs of the 24 OXA-244-producing  E. coli  in 
this study were uploaded to SeqSphere+ version 5.1.0 
(Ridom GmbH, Münster, Germany (http://www.ridom.
de/seqsphere/)) using the Enterobase  E. coli  cgMLST 
scheme based on 2,513 genes with a cluster distance 
threshold of ≤ 10 allele differences.
Ethical statement
Data on cases were collected as part of the national 
CPO surveillance according to guidelines for the pre-
vention of spread of CPO by the Danish Health Authority 
according to which, both patients and treating medical 
doctor may be contacted for investigation [12]. All data 
were anonymised and cannot be inferred directly or 
indirectly to a person.
Results
Patients with OXA-244-producing Escherichia 
coli
From January 2016 to August 2019, 24 OXA-244-
producing E. coli  isolates were detected in 23 patients 
in Denmark (Figure 1). From one of the patients, an 
OXA-244-producing  E. coli  and an OXA-244/NDM-5-
producing  E. coli  were obtained from the same faecal 
sample; both isolates were included in the study (Table 
1). The remaining 22 OXA-244-producing E. coli isolates 
were obtained from blood samples (n =  2), urine 
samples (n = 18) and faecal samples (n = 2).
The 24 isolates were collected from hospitals and pri-
mary healthcare facilities across all five Danish regions 
(Figure 2, Table 1).
The age of the patients ranged from 5 to 79 years, with 
a median of 58 years, 20 were female and three were 
male. In comparison, during the study period, 63.5% 
(136/214) of patients with carbapenemase-producing E. 
coli were female in the Danish CPO surveillance, while 
the majority of the patients with OXA-244-producing E. 
coli in our study were female (p < 0.05).
Of the 23 patients, 13 had been travelling 6 months 
before detection of the OXA-244-producing  E. 
coli  isolates, six had no reported history of recent 
travel and for the remaining four patients, travel infor-
mation was unavailable (Table 1). Of the 13 patients 
reporting travel abroad within 6 months before detec-
tion of the OXA-244-producing  E. coli  isolate, seven 
had been to countries in Northern Africa (six to Egypt, 
one to Tunisia).
During the study period, Carbapenemase-producing E. 
coli isolates were detected from 214 patients; of these, 
21 patient samples were taken at a general practi-
tioner, 11 of these patients had OXA-244-producing  E. 
coli  isolates. Furthermore, OXA-244-producing  E. 
coli isolates were detected from the samples from three 
patients visiting an emergency department and from 
nine patients hospitalised at different hospital wards.
Data from DNPR were available for the 13 patients with 
positive samples before February 2019. None of the 13 
patients had been hospitalised at the same time at the 
same hospitals. Among these 13 patients, seven had 
not been hospitalised in Denmark, from January 2016 
to February 2019, and their samples were either from 
a visit at the general practitioner or at the emergency 
department.
Questionnaire of food consumption and 
animal contact
Fifteen of 19 patients with OXA-244-producing  E. 
coli  isolates during January 2018 to August 2019 were 
interviewed on the phone, while four patients were 
unavailable.
All 15 patients were eating meat and eggs. Four patients 
had been in contact with cats, 12 with dogs and two 
with wild birds. None of the patients had been in con-
tact with livestock, hunting animals or reptiles.
Phylogenetic analysis
The 24 OXA-244-producing  E. coli  isolates belonged 
to six different STs; ST10 (n = 1), ST38 (n = 13), ST69 
(n = 6), ST167 (n = 2), ST361 (n = 1) and ST3268 (n = 1) 
(Table 2), and 15 had an ESBL gene (bla CTX-M-14b, bla CTX-
M-15 or bla CTX-M-27) and one had a plasmid-encoded AmpC 
gene (bla  CMY-2). Genes encoding colistin resistance, 
i.e.  mcr  genes, were not detected in any of the iso-
lates. In four isolates, bla OXA-244 was the only detected 
resistance gene (Table 2).
One patient had both an OXA-244-producing ST167  E. 
coli  (CPO20180141) and an OXA-244/NDM-5-producing 
ST167  E. coli  (CPO20180142), but the two isolates did 
not cluster together in the cgMLST analysis and they 
had different resistance gene profiles (Table 2).
Three phylogenetic clusters were detected by cgMLST 
for the 24 isolates from this study (Table 2).
Core-genome multilocus sequence typing clusters
The five isolates in Cluster 1 belonged to ST38 (Table 
2). The samples were obtained from December 2017 
to May 2019 from three different regions in Denmark. 
Data from DNPR until February 2019 did not detect any 
overlapping hospitalisations between the first three 
patients. Travel information was missing for the first 
patient in this cluster. Six months prior to detection 
of the OXA-244- producing E. coli  isolates, the second 
patient had been to Greece, the third patient had 
visited Egypt, the fourth patient had travelled to Egypt, 
Turkey as well as Italy, and the last patient had been 
to Sweden and Portugal. There were no geographical 
associations for place of residence among the patients 
in Cluster 1.
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Both isolates in Cluster 2 belonged to ST38 (Table 2). 
The isolates were sampled in May 2016 and June 2018 
in the same region. The first patient had not been trav-
elling 6 months before detection of the ST38 OXA-244-
producing  E. coli  isolate, whereas travel information 
was missing for the other patient. No epidemiologic 
links regarding hospitalisation or place of residence 
were detected between the patients.
The three isolates in Cluster 3 belonged to ST69 (Table 
2). The samples were from three different regions and 
the patients also lived in different parts of the coun-
try. Unfortunately, DNPR data were not available for 
these patients as they all were detected after February 
2019. The first patient had been to Poland and Austria 
6 months before detection and the second patient had 
been to Egypt, while travel information was unavail-
able for the third patient.
Discussion
In recent years, several hospital-related outbreaks with 
CPO have been observed in Denmark [11]. The increase 
in OXA-244-producing  E. coli  in Denmark described 
here did not appear to be related to Danish hospi-
tal outbreaks. Unfortunately, travel information was 
not available for all patients. Despite this, repeated 
import from abroad of the OXA-244-producing  E. 
coli  isolates appears likely. Many of the patients had 
been travelling 6 months before detection of the OXA-
244-producing E. coli, predominantly to Northern Africa 
destinations. Intestinal persistence of CPO for more 
than 6 months has been reported, so a limitation in 
our study could by the lack of information about travel 
prior to 6 months [20]. It could be speculated that the 
OXA-244-producing  E. coli  could have been acquired 
during travel abroad longer than 6 months ago (e.g. 
a single patient reported travel to Egypt 5 years ago, 
data not shown).
Among the 15 patients interviewed by phone, 12 
reported contacts to dogs and four to cats. To our 
knowledge, OXA-244-producing  E. coli  isolates have 
neither been reported from dogs nor cats, but a recent 
study reported on OXA-181-producing  E. coli  isolates 
obtained from dogs and cats after hospitalisation in a 
veterinary clinic in Switzerland [21].
All 15 patients interviewed by phone were eating meat, 
but none of them had been in direct contact with live-
stock. OXA-244-producing  E. coli  have neither been 
reported from meat nor from livestock. More generally, 
CPO are very rarely reported from livestock and meat 
in Europe. In contrast to Europe, dissemination of CPO 
among livestock are more common in China, India and 
Northern Africa [22].
Community sources for the OXA-244-producing  E. 
coli  isolates seem possible since many of the patients 
had not been hospitalised and the  E. coli  isolates 
belonged to STs that are present in the community 
[23-32]. The ECDC RRA identified one main geographi-
cally dispersed ST38 OXA-244-producing E. coli cluster 
with chromosomal-encoded bla  OXA-244 present in all 10 
countries, including Denmark, that submitted data for 
the RRA [10]. The exact location (plasmid or chromo-
somal) of  bla  OXA-244  was not investigated in our study 
as is would require utilisation of long read sequencing 
techniques (e.g. MinION and PacBio). The  bla  OXA-
244  gene can be part of the Tn51098  transposon [33]. 
This transposon has been reported at the same loca-
tion of the chromosomal position among different STs 
[34].
In conclusion, an increase in OXA-244-producing  E. 
coli  has been detected in Denmark and other coun-
tries in Europe. Import of OXA-244  E. coli  isolates 
from travelling abroad seems most likely for the 
majority of cases. Community sources of infections 
are also possible, as many of the patients had no 
history of hospitalisation. Furthermore, many of the E. 
coli  isolates belonged to STs that are present in the 
community. It was not possible to point at a single 
country or a community source as risk factor for 
acquiring OXA-244-producing E. coli isolates.
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